Seoul
Chief MD, Gangnam
Duk-ha Kim
The trust our patients have placed in this clinic was built on conviction and principle. We intend to hold to both, unchanged, through the next hundred years.
Botulinum toxin guide — body muscles
Body Toxin
Body toxin means botulinum toxin type A injected into a skeletal muscle outside the face, usually the trapezius for the shoulder line or the gastrocnemius for the calf. Neither area appears as an approved indication on the U.S. BOTOX labels or the Korean MFDS records checked for this page, so this is an off-label decision made by the treating doctor — legal for a clinician to make, but reviewed by no regulator, and supported by small published studies.
- What it acts on
- Skeletal muscle at the neuromuscular junction — not fat
- Label status
- Trapezius and calf cosmetic use not listed on the U.S. or Korean labels checked here
- Label warning
- U.S. boxed warning on distant spread of toxin effect
- Units
- Defined per product; not convertible between brands
What do clinics mean by “body toxin”?
Body toxin is a menu name, not a product name. It refers to botulinum toxin type A injected into a skeletal muscle outside the face — most often the trapezius, which shapes the shoulder line, or the gastrocnemius in the calf. The drug belongs to the same class used on approved wrinkle menus; what changes is the muscle, the dose and, above all, whether that use appears on the label at all.
Sources: FDA label — BOTOX CosmeticMFDS drug product record — Nabota 50 U
How does botulinum toxin act on a body muscle?
Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction, so the injected muscle contracts with less force. Sustained reduced contraction can reduce the bulk of that muscle over time. That is a description of the mechanism, not a promise of a result, and because the drug acts on the neuromuscular junction it does nothing to fat.
Sources: FDA label — BOTOX (therapeutic)FDA label — BOTOX Cosmetic
Is injecting the trapezius or calf an approved use?
Not in any record checked for this page. The U.S. BOTOX and BOTOX Cosmetic labels list the uses they were approved for, and cosmetic injection of the trapezius or the calf is not among them; the Korean MFDS records for Nabota and Meditoxin likewise do not list these areas. Off-label is not a synonym for illegal — a licensed doctor may prescribe outside the label on clinical judgement — but it does mean no regulator has reviewed this use, and the labels state that safety and effectiveness have not been established for uses that are not listed. The practical consequence is not “avoid this”, it is “you are the one who has to weigh the evidence level and the risk before consenting”.
Sources: FDA label — BOTOX (therapeutic)FDA label — BOTOX CosmeticMFDS drug product record — Nabota 50 UMFDS drug product record — Meditoxin
What does the published trapezius trial actually show?
One randomized trial exists: 30 healthy Chinese women, followed for 6 months. Its comparison was between two injection techniques — a conventional pattern and a nerve-distribution-based pattern — not between toxin and no treatment, so it cannot tell you how much of the change came from the injection itself. Mean muscle-thickness reduction in the two technique groups was 0.27±0.08 cm and 0.21±0.09 cm at 3 months (p=0.047), and 0.28±0.06 cm and 0.2±0.09 cm at 6 months (p=0.041). The authors reported no severe side effects, but shoulder and neck strength were not measured at all, so the trial says nothing about whether function was affected. Thirty participants in a single population, with no untreated arm, is a starting point — not a general effect size you can expect.
Sources: Wang L et al., Aesthetic Plast Surg 2024;48(6):1210-1217
What did the calf study find about walking and balance?
One uncontrolled prospective study measured gait after gastrocnemius injection in 15 healthy adult women, followed for 3 months. Spatiotemporal measures — step length, cadence, walking speed — showed no significant change. Dynamic balance-control measures did change for the worse: in the sagittal plane during double support (p=0.033 and p=0.050) and in the frontal plane during early single support (p=0.038). In plain terms, walking looked unaffected while fine balance control measured worse. With 15 participants and no control group this is not a quantified risk, but it is the finding most specific to calf injection, and it is the one to raise if you run, hike, wear heels or spend long days on your feet.
Sources: Lin SH, Wang TM, Lu TW, Gait Posture 2026;123:109994
How long does the effect on the trapezius or calf actually last?
The only follow-up windows in the sources behind this page are 6 months for the trapezius trial and 3 months for the calf study, so neither trial tells you what happens after those points. The trapezius trial measured muscle-thickness reduction at 3 months and again at 6 months, and the reduction was still present at the later time point in both technique groups (0.28±0.06 cm and 0.2±0.09 cm) — but the trial compared two injection patterns against each other, not toxin against no treatment, so it cannot show how much of that 6-month reduction is the toxin itself rather than the injection-technique variable it was actually designed to test. The calf study only followed participants to 3 months, had no untreated comparison group, and did not re-measure afterward, so no source here says whether the balance changes it found improve, persist or worsen beyond that point. Neither study reports what happens once the drug’s known mechanism — reduced acetylcholine release at the neuromuscular junction — wears off and muscle activity returns, because neither followed anyone that long. What actually determines how long a visible change holds is dose, the specific muscle injected, and individual variation in how quickly nerve signalling recovers, and none of that is quantified for body use in the sources cited here. The consultation question that follows is what evidence the clinic is using for its stated interval — the 3- or 6-month windows these two small trials actually measured, or a figure carried over from on-label facial use of the same drug class, which is a different muscle and a different question.
Sources: Wang L et al., Aesthetic Plast Surg 2024;48(6):1210-1217Lin SH, Wang TM, Lu TW, Gait Posture 2026;123:109994FDA label — BOTOX (therapeutic)
What does the boxed warning say, and who should not be injected?
The U.S. BOTOX labels carry a boxed warning headed “WARNING: DISTANT SPREAD OF TOXIN EFFECT”: effects may spread from the injection site hours to weeks after injection and produce symptoms of botulinum toxicity, including swallowing and breathing difficulties that can be life threatening. That warning attaches to the product, not to a particular treatment area, so it applies to body injection as well. The BOTOX Cosmetic label lists two contraindications — hypersensitivity to any botulinum toxin preparation, and infection at the proposed injection site — and warns that people with pre-existing neuromuscular disorders may be at increased risk of systemic effects. Swallowing or breathing difficulty after an injection needs immediate medical attention.
Sources: FDA label — BOTOX (therapeutic)FDA label — BOTOX Cosmetic
Why can’t doses be compared between products?
Units of botulinum toxin are defined by each manufacturer’s own potency assay, and the U.S. BOTOX label states that its units are not interchangeable with other botulinum toxin products. The Korean MFDS records for Nabota and for Meditoxin each define their own units the same way. So “100 units” at one clinic and “100 units” at another describe the same amount only when the product is the same. Settle the product name first, then the unit count — a number without a product name carries no information.
Sources: FDA label — BOTOX CosmeticMFDS drug product record — Nabota 50 UMFDS drug product record — Meditoxin
What should you settle before consenting to the injection?
Ask for the product name, the number of units, the exact muscle, and who performs the injection — and have it recorded, not described verbally. Because this is an off-label use, also ask what the doctor expects, what they explicitly do not claim, and what the plan is if weakness appears after you leave. Disclose neuromuscular disease, pregnancy or breastfeeding, infection at the site, medicines that can affect neuromuscular transmission such as aminoglycoside antibiotics, previous toxin injections and their dates, and how much you rely on the muscle in daily life: lifting, sport, heels, long walking days.
Sources: FDA label — BOTOX CosmeticLin SH, Wang TM, Lu TW, Gait Posture 2026;123:109994
What is the course afterwards, and what needs a call?
Effect is not immediate — the labels describe assessment at intervals of days to weeks after injection, not on the day. Local reactions such as injection-site pain, bruising or headache are described on the label. Contact the treating clinic for weakness that interferes with daily tasks, a change in your walking or balance, neck or shoulder weakness, or any symptom spreading beyond the injected area. Swallowing difficulty, speech difficulty, breathing difficulty, drooping eyelids, double vision or generalized weakness are emergencies: seek care immediately, and be able to say which product was injected, how many units and on what date.
Sources: FDA label — BOTOX (therapeutic)FDA label — BOTOX Cosmetic
How is this different from other body treatments?
Toxin acts at the neuromuscular junction, so muscle is the only tissue it acts on. Injection lipolysis targets fat, and body devices using radiofrequency or focused ultrasound target fat or skin; none of these substitute for one another. If a shoulder line or a calf shape is driven mainly by fat, by bone structure or by posture, a muscle-targeted drug will not change it. Which component dominates is an in-person assessment — and when the answer is “not muscle”, the honest conclusion is that this injection is the wrong tool rather than a smaller dose of the right one.
Sources: FDA label — BOTOX (therapeutic)
Trapezius or calf: the label status is the same, the evidence is not
These two areas are often sold as one menu item, but they do not rest on the same published work. Compare what each study measured, in how many people, and against what comparator — then ask the clinic which of it applies to you.
| Area | Status in the labels checked here | Published study cited on this page | Main limitation to weigh |
|---|---|---|---|
| Trapezius (shoulder line) | Not listed as an indication on the U.S. BOTOX or BOTOX Cosmetic labels, nor on the Korean MFDS records for Nabota and Meditoxin | Randomized trial, 30 healthy women, 6-month follow-up, comparing two injection techniques; mean thickness reduction in the range of about 0.2-0.28 cm | No untreated control arm, and shoulder and neck strength were never measured, so effect on function is unknown |
| Calf (gastrocnemius) | Also not listed on any of those U.S. or Korean labels | Uncontrolled prospective study, 15 healthy women, 3-month follow-up; gait speed, cadence and step length unchanged, dynamic balance-control measures worsened | Fifteen participants and no control group; the balance finding is a reason to discuss the risk, not a number you can apply to yourself |
| Glabellar lines (shown only for contrast) | Listed as an approved cosmetic indication on the U.S. BOTOX Cosmetic label | Not summarised here — this row exists only to show what a reviewed, label-listed use looks like next to one that is not | An approved indication in one area does not transfer to the trapezius or the calf; approval is granted use by use |
This table compares regulatory status and evidence level, not results. It is not a ranking, not an efficacy comparison, and not a recommendation for either area.
Medical care at Abijou
Care is provided by the medical team at the branch you select. These clinicians lead the three branches linked from this guide; confirm the doctor assigned to your visit with that branch.
Chief MD, Myeongdong
Cheol-su Yoon
I want to be thinking about how the patient feels right up to the last moment of the procedure.
Chief MD, Hongdae
Jae-wook Kim
I will give my best with the attentiveness to catch even the smallest change.
Listed branch medical team — not a medical-review byline for this article.
Frequently asked questions
Is “shoulder-line injection” the same thing as trapezius toxin?
Usually yes, but the menu name does not tell you that — so confirm it. Clinic menus use shoulder-line, shoulder-slimming and trapezius injection for the same botulinum toxin procedure, while other shoulder menus may refer to entirely different treatments. Ask which drug, which muscle and how many units before you treat two quotes as the same thing.
Does body toxin remove muscle?
No. Botulinum toxin does not remove tissue; it temporarily reduces how strongly the injected muscle contracts, and reduced contraction over time can reduce that muscle’s bulk. Nothing is excised, and the block is not permanent — the published trapezius trial followed participants for 6 months and the calf study for 3 months, which is how long they observed, not how long an effect lasts.
Why does blocking a nerve signal change the size of a muscle?
Because a muscle that contracts less is used less, and muscle bulk responds to use. The toxin blocks acetylcholine release at the neuromuscular junction, so the signal reaching the injected muscle is weakened; the reduction in size is a downstream consequence of that, not a direct effect on the tissue. This mechanism is why the treatment cannot affect fat, and why the result depends on how much of the shape in question is actually muscle.
Is this the same procedure as toxin for facial wrinkles?
Same class of drug, different regulatory footing. Glabellar lines and other facial areas appear as approved indications on the U.S. BOTOX Cosmetic label; the trapezius and the calf do not appear on that label or on the Korean MFDS records checked here. The doses and muscles differ too. Treat the familiarity of facial toxin as a reason to ask more questions about the body version, not fewer.
Is body toxin an alternative to fat-dissolving injections or body-contouring devices?
No — they act on different tissue, so they are not substitutes. Toxin acts on muscle at the neuromuscular junction, injection lipolysis targets fat, and radiofrequency or focused-ultrasound body devices target fat or skin. This page holds no comparative data between them, and choosing between them starts with an in-person assessment of which tissue actually accounts for the shape you want to change.
Is a Korean product such as Nabota or Meditoxin better than BOTOX for body areas?
This page has no head-to-head data for body muscles, so it cannot rank them. What is documented is that none of these products lists trapezius or calf cosmetic injection as an approved indication in the U.S. or Korean records checked here, and that units are defined per product and are not interchangeable. A lower unit price attached to a different product is not a discount on the same thing.
Does it hurt, and can I fly the same week?
Injection-site pain and bruising are described on the label as possible reactions, and no procedure-specific pain score for these body areas is available in the studies cited here. Neither cited study reports flight timing, so no schedule can be promised from this page. Ask the treating clinic directly, and plan your dates so you still have contact with them during the weeks in which delayed effects could appear.
Can I exercise, wear heels or lift heavy things afterwards?
Discuss this before the injection, not after, because it is the part the published evidence is weakest on. The trapezius trial did not measure shoulder or neck strength, and the calf study found dynamic balance-control measures worsened even though walking speed and step length did not change. If your work or sport depends on those muscles, that missing data is directly relevant to you, and the treating doctor should tell you what they expect and what they cannot predict.
How many sessions are needed, and how long does the effect last?
No session count or duration can be given from the sources on this page. The trapezius trial followed participants for 6 months and the calf study for 3 months; those are observation windows, not durations of effect, and neither study was designed to establish a repeat interval. Repeat intervals on the labels apply to the approved indications, which do not include these areas, so ask the treating doctor what interval they use and on what basis.
Who should not receive botulinum toxin at all?
The U.S. BOTOX Cosmetic label lists two contraindications: hypersensitivity to any botulinum toxin preparation, and infection at the proposed injection site. It also warns that people with pre-existing neuromuscular disorders, such as myasthenia gravis or Lambert-Eaton syndrome, may be at increased risk of systemic effects. Disclose neuromuscular disease, medicines affecting neuromuscular transmission, pregnancy or breastfeeding, and any previous toxin injection with its date.
Which side effects are specific to body muscles rather than the face?
Muscle weakness in a limb or shoulder you actually load, and changes in balance, are the body-specific concerns. The boxed warning on distant spread of toxin effect applies to the product regardless of the injected area. Beyond that, the calf study recorded worsened dynamic balance control at three months in 15 participants with no control group, and the trapezius trial never measured shoulder or neck strength — so for function the honest summary is one weak signal and one unmeasured question.
If it is off-label, is it illegal to have it done in Korea?
Off-label means the use has not been reviewed and approved by the regulator, not that the treatment is prohibited; prescribing outside the label on clinical judgement is a recognised part of medical practice. What changes for you is the standard of evidence: an approved indication has been assessed by an agency, and this one has not, so the published studies and the doctor’s reasoning are all you have to weigh. This page is not legal advice, and rules on use and advertising differ by country.
How should I compare quotes between clinics?
Align what the quotes contain before you compare the amounts. Confirm the product name, the unit count, the muscle and the number of injection points, whether the price covers one session or a package, and what follow-up is included if weakness appears. Because units are not interchangeable between products, two quotes naming the same number of units are not comparable unless they also name the same product.
Who is this suitable for, and can I have it during a short trip to Korea?
Suitability is decided at an in-person assessment, including the question of whether your shoulder or calf shape is actually driven by muscle. For a short trip, the timing problem is follow-up: the effect is assessed over days to weeks, and the boxed warning describes effects that can appear hours to weeks after injection, which may be after you have flown home. Tell the clinic your travel dates, medicines, medical history and physical demands, and agree in advance how you will reach them once you are back.
How Abijou works
We started in Gangnam in 2006 and the network now runs 17 branches across Korea. The line we work to is skin transformation woven into everyday life — care you can keep up with, rather than one dramatic change.
- Across the 17 branches in Seoul, Gyeonggi, Incheon and Busan: over 1,000 medical professionals and more than 350 certified medical devices
- Authentic products only, in appropriate amounts — the treatment is fitted to the condition, not to a package
- Prices are quoted from each branch’s published price list as it stands
Contact and location
- Phone
- 1544-0377
Free Consultation
Booking happens at the branch
There is no inquiry form on this page. Once you have picked a branch above, open that branch’s site or the official reservation center and choose a time yourself.
- No deposit and no online prepayment — everything is paid at the visit
- Per-treatment prices are published for each branch on the official reservation center
- English, Japanese and Chinese are supported alongside Korean